SCHEDULE: FMR LLC Discloses 10.2% Stake in Eikon Therapeutics

FMR LLC, along with Abigail P. Johnson, has reported beneficial ownership of 10.2% of Eikon Therapeutics Inc.'s common stock as of September 30, 2026.

Summary

• FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, indicating their beneficial ownership of Eikon Therapeutics Inc. common stock.
• As of September 30, 2026, the total beneficial ownership is reported at 5,520,152 shares, representing 10.2% of the class of securities.
• FMR LLC holds sole voting power over 5,518,822 shares and sole dispositive power over 5,520,152 shares.
• Abigail P. Johnson has sole dispositive power over 5,520,152 shares, with no shared voting or dispositive power reported for either entity.
• The filing is an amendment (Amendment No. 2) to a previous Schedule 13G filing.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing, indicating significant institutional ownership and a stable, long-term investment perspective from a major financial entity.

Positives

• Significant institutional ownership by FMR LLC, a major financial services firm.
• Abigail P. Johnson, a key figure in FMR LLC, also has a reported beneficial ownership, suggesting strong conviction.
• The ownership stake of 10.2% indicates a substantial investment in Eikon Therapeutics Inc.

Negatives

• No specific negative financial or operational information is presented in this Schedule 13G filing, as it primarily concerns ownership disclosure.

Risks

• The filing does not explicitly detail risks associated with Eikon Therapeutics Inc. itself, but rather pertains to the reporting persons' investment.
• Potential future changes in FMR LLC's ownership stake could impact Eikon Therapeutics' stock.

Future Outlook

This filing does not contain forward-looking statements or guidance from Eikon Therapeutics Inc. It is a disclosure of beneficial ownership by FMR LLC and Abigail P. Johnson.

Management Comments

• FMR LLC and Abigail P. Johnson certify that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that the filing of a Schedule 13G by a major institutional investor like FMR LLC signifies a passive investment approach, typically indicating confidence in the company's long-term prospects without seeking to control management. This is common in the biotechnology sector where significant capital is required for development.

Stakeholder Impact

• Shareholders: The significant stake held by FMR LLC may provide a degree of stability and confidence in the company's stock.
• Management of Eikon Therapeutics Inc.: The passive nature of the investment suggests no immediate intent to influence corporate control.

Next Steps

• FMR LLC and Abigail P. Johnson will continue to hold their beneficial ownership stake in Eikon Therapeutics Inc.
• Future amendments to this Schedule 13G will be filed if there are material changes in ownership.

Key Dates

Keywords

Eikon Therapeutics, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Investment